scholarly journals Extramedullar Plasmacytoma Arising from the Nasal Septum

2005 ◽  
Vol 84 (11) ◽  
pp. 720-722 ◽  
Author(s):  
Byoung J. Baek ◽  
Seong W. Kim ◽  
Hoon Park ◽  
Jin K. Park ◽  
Kyung Y. Han ◽  
...  
Keyword(s):  
Nasal Septum ◽  
Biopsy Specimen ◽  
Extramedullary Plasmacytoma ◽  
Screening Tests ◽  
Bence Jones Protein ◽  
Light Chain Type ◽  
History Of ◽  
Chain Type ◽  
Rule Out

We report a rare case of extramedullary plasmacytoma of the nasal septum in a 65-year-old woman. She presented with a 2-month history of left-sided nasal obstruction and intermittent blood-tinged nasal crusting. Nasal endoscopy revealed that a dark-red mass had arisen from the nasal septum; no evidence of invasion to adjacent tissues was seen. A biopsy specimen was diagnosed as a plasmacytoma (kappa light chain—type). Serum and urine electrophoresis failed to detect any myeloma component or Bence Jones protein. All other screening tests to rule out multiple myeloma were negative. These findings confirmed the diagnosis of extramedullary plasmacytoma. The mass was completely removed via an endoscopic approach. No recurrence was noted at the 2-year follow-up.

scholarly journals Primary Extramedullary Plasmacytoma of Maxillary Sinus

2013 ◽  
Vol 6 (1) ◽  
pp. 51-53
Author(s):  
Chinmaya Sundar Ray ◽  
Aparajita Mishra ◽  
Rabindra Kumar Khatua ◽  
Prasenjit Baliarsingh
Keyword(s):  
Maxillary Sinus ◽  
Biopsy Specimen ◽  
Lateral Wall ◽  
Extramedullary Plasmacytoma ◽  
Screening Tests ◽  
Bence Jones Protein ◽  
Light Chain Type ◽  
Chain Type ◽  
Rule Out

ABSTRACT A rare case of extramedullary plasmacytoma of maxillary sinus in a 58-year-old man presenting with right-sided nasal obstruction and intermittent blood tinged nasal crusting. Nasal endoscopy revealed that a dark red colored mass arising from the lateral wall of nose. A biopsy specimen was diagnosed as plasmacytoma (Kappa light chain type). Serum and urine electrophoresis failed to detect any myeloma component or Bence-Jones protein. All other screening tests to rule out multiple myeloma were negative. These findings confirmed the diagnosis of extramedullary plasmacytoma. The mass was completely excised by lateral rhinotomy approach. No recurrence has been noted at the end of 6 months follow-up. How to cite this article Ray CS, Mishra A, Khatua RK, Baliarsingh P. Primary Extramedullary Plasmacytoma of Maxillary Sinus. Clin Rhinol An Int J 2013;6(1):51-53.

scholarly journals Nasal septum extramedullary plasmacytoma

2013 ◽  
Vol 70 (2) ◽  
pp. 221-224 ◽  
Author(s):  
Branislav Belic ◽  
Slobodanka Mitrovic ◽  
Snezana Arsenijevic ◽  
Ljiljana Erdevicki ◽  
Jasmina Stojanovic ◽  
...  
Keyword(s):  
Nasal Cavity ◽  
Nasal Septum ◽  
Plasma Cells ◽  
Malignant Tumors ◽  
Combined Therapy ◽  
Extramedullary Plasmacytoma ◽  
Screening Tests ◽  
The Right ◽  
Nose And Throat

Introduction. Plasmacytomas are malignant tumors characterized by abnormal monoclonal proliferation of plasma cells. They originate in either bone - solitary osseous plasmacytoma, or in soft tissue - extramedullary plasmacytoma (EMP). EMP represents less than 1% of all head and neck malignancies. Case report. We presented a case of EMP of the nasal septum in a 44-year-old male who had progressive difficulty in breathing through the nose and frequent heavy epistaxis on the right side. Nasal endoscopy showed dark red, soft, polypoid tumor in the last third of the right nasal cavity arising from the nasal septum. The biopsy showed that it was plasmacytoma. Bence Jones protein in the urine, serum electrophoresis, bone marrow biopsy, skeletal survey and other screening tests failed to detect multiple myeloma. This confirmed the diagnosis of EMP. The mass was completely removed via an endoscopic approach, and then, 4 week later, radiotherapy was conducted with a radiation dose of 50 Gray. No recurrence was noted in a 3-year follow- up period. Conclusion. EMP of the nasal cavity, being rare and having long natural history, represents a diagnostic and therapeutic challenge for any ear, nose and throat surgeon. Depending on the resectability of the lesion, a combined therapy is the accepted treatment.

Primary carcinoid tumour of nasal septum

2008 ◽  
Vol 123 (7) ◽  
pp. 789-792 ◽  
Author(s):  
T Galm ◽  
N Turner
Keyword(s):  
Nasal Septum ◽  
World Literature ◽  
Carcinoid Syndrome ◽  
Carcinoid Tumour ◽  
Primary Tumour ◽  
Neck Region ◽  
Head And Neck Region ◽  
Carcinoid Tumours ◽  
History Of

AbstractObjective:We present the first reported case of primary carcinoid tumour of the nasal septum.Method:Case report of our experience of a carcinoid tumour of the nasal septum. We discuss our clinical, radiological and pathological findings.Result:An 83-year-old woman presented with a history of left-sided nasal blockage. Clinical examination showed a unilateral, left-sided nasal polyp. Further imaging and histological analysis confirmed this to be a carcinoid tumour. Carcinoid tumours outside the gastrointestinal tract are rare. There have been reports of carcinoid tumours in the head and neck region, but no published cases occurring in the nasal septum. Our management involved wide surgical resection with regular follow up to monitor for recurrence and for the development of carcinoid syndrome. Four years from initial presentation, the patient remained free of the primary tumour and had displayed no signs or symptoms suggestive of carcinoid syndrome.Conclusion:To the authors' best knowledge, and after searching the world literature, the presented case represents the first report of primary carcinoid tumour of the nasal septum. Despite its rarity, this tumour should be considered as part of the differential diagnosis, as timely recognition and intervention are critical for successful treatment.

Extramedullary Plasmacytoma of The Frontal Sinus: A Case Report

FACE ◽  
2021 ◽  
pp. 273250162110536
Author(s):  
Joshua Harrison ◽  
Samantha Marley ◽  
Shawhin Shahriari ◽  
Christian Bowers ◽  
Anil Shetty
Keyword(s):  
Frontal Sinus ◽  
Surgical Excision ◽  
Extramedullary Plasmacytoma ◽  
High Rate ◽  
Solitary Plasmacytoma ◽  
Case Presentation ◽  
Long Term Follow Up ◽  
History Of

We report a rare case of an extramedullary plasmacytoma (EMP) in the frontal sinus with an indolent clinical presentation. Although a history of trauma was absent, the initial diagnosis was a mucocele, based on the radiological findings. Upon surgical excision, the patient was found to have an EMP. EMP, a form of solitary plasmacytoma, has a significantly high rate of conversion to multiple myeloma. This mandates long-term follow-up, even after successful radiotherapy and/or resection. While radiation therapy is generally considered a first line treatment for EMP, surgical intervention may provide optimal treatment in complicated cases. This case presentation highlights the prognosis of patients diagnosed with EMP.

scholarly journals Asystole in an older patient with recurrent falls. Case report

Case reports ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. 77-83
Author(s):  
William Fernando Bautista-Vargas
Keyword(s):  
Case Report ◽  
Older Patients ◽  
Implantable Devices ◽  
Loop Recorder ◽  
General Terms ◽  
Recurrent Falls ◽  
History Of ◽  
Rule Out

Introduction: Recurrent falls are a usual problema in older patients. It is therefore important to learn how to differentiate a pathological or syncopal episode from a simple stumbling fall, especially in patients who have limitations for communicating clearly and are poorly understood, in general terms, during the medical consultation. Implantable loop recorders (ILR) have been used as an investigation tool in selected cases of recurrent falls in older patients. Consequently, this case report aims to describe its usefulness in this type of patients.Case presentation: An 87-year-old female patient, hypertensive, with a history of recent stroke and frequent falls —referred to as stumbling—, received an implantable loop recorder due to atrial fibrillation. During one follow-up appointment, a 36-second pause related to a fall was documented, so a bicameral pacemaker was implanted.Conclusions: Evaluating repeated falls in older patients is complex; it must be done in detail to rule out syncopal episodes. Implantable devices to diagnose arrhythmic causes are useful and allow achieving accurate diagnoses and establish specific behaviors aimed at improving the quality of life of patients.

Extramedullary plasmacytoma of the larynx

1993 ◽  
Vol 107 (11) ◽  
pp. 1049-1051 ◽  
Author(s):  
Izumi Mochimatsu ◽  
Mamoru Tsukuda ◽  
Shuji Sawaki ◽  
Yukio Nakatani
Keyword(s):  
Radiation Therapy ◽  
Nasal Cavity ◽  
Histological Examination ◽  
Staining Technique ◽  
Extramedullary Plasmacytoma ◽  
Immunoperoxidase Staining ◽  
Left Nasal Cavity ◽  
Bence Jones Protein ◽  
History Of ◽  
Nasal Bleeding

AbstractA case of IgD myeloma in a 54-year-old male with a long-standing history of extramedullary plasmacytoma involving the larynx is reported.The patient was treated with radiation therapy and laryngectomy. Twelve years later, he complained of nasal bleeding. On examination he was found to have large masses in the left nasal cavity and in the left supraclavicular region. Histological examination of both lesions showed plasmacytoma. Serum immunoglobulin studies revealed an IgD monoclonal spike of the lambda type. Bence-Jones protein was present. Using the immunoperoxidase staining technique, cytoplasmic monoclonal IgD was detected.

Solitary extramedullary plasmacytoma of the larynx: a rare cause of dysphonia

2020 ◽  
Vol 13 (9) ◽  
pp. e234478
Author(s):  
Hannes Hermann Brandt ◽  
Steffi Johanna Brockmeier ◽  
Nora Tetter
Keyword(s):  
Plasma Cell ◽  
Progressive Disease ◽  
Thyroid Cartilage ◽  
Extramedullary Plasmacytoma ◽  
Secondary Amyloidosis ◽  
Systemic Involvement ◽  
Amyloid Deposits ◽  
History Of ◽  
Solitary Extramedullary Plasmacytoma

Solitary extramedullary plasmacytoma (SEP) of the larynx is a rare haematological malignancy and an infrequent cause of persisting dysphonia. We present the case of a 54-year-old woman with a long-standing history of dysphonia. While clinical examination showed a rather inconspicuous prominent right vestibular fold, an MRI revealed a laryngeal mass with erosion of the thyroid cartilage. A biopsy taken during rigid endoscopy demonstrated plasma cell infiltration with light chain restriction amidst amyloid deposits. After exclusion of systemic involvement, the diagnosis of an SEP of the larynx with secondary amyloidosis was made. The patient received primary radiation therapy. Another biopsy taken 3 months after the end of therapy did not show any signs of ongoing neoplastic plasma cell disease. The patient was therefore considered to be in remission. She is currently receiving regular follow-up and has not shown signs of persistent or progressive disease for the past 18 months.

New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation

2016 ◽  
Vol 54 (6) ◽  
Author(s):  
Anna Caldini ◽  
Chiara Nozzoli ◽  
Alessandro Terreni ◽  
Michela Staderini ◽  
Margherita Berardi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Plasma Cells ◽  
Bence Jones Protein ◽  
Biological Drugs ◽  
History Of ◽  
Novel Therapeutic Strategies ◽  
Urine And Serum ◽  
Serum And Urine

AbstractMultiple myeloma (MM) is characterized, in about 80% of cases, by the production of monoclonal intact immunoglobulin and more than 95% of them have elevated concentrations of involved (i.e. of the same class of intact immunoglobulin) free light chain (FLC). The introduction of novel therapeutic strategies has changed the natural history of the disease, leading to new manifestations of relapse. Light chain escape (LCE) is a pattern of relapse in which the FLC increase is not accompanied by a concomitant raise of the original monoclonal component (MC). Here we present a case of a 55-year-old man with an IgG kappa MM stage III diagnosed in September 2007. At presentation an IgG kappa MC and urine Bence Jones protein (BJP) kappa were present. Bone marrow biopsy (BMB) showed the presence of 80% monotypic kappa plasma cells (PCs). The patient received bortezomib, thalidomide, dexamethasone before undergoing a double autologous stem cell transplantation (ASCT) in October 2008 and April 2009. In May 2011 he relapsed showing the same pattern of presentation and treatment with lenalidomide and dexamethasone was started. ln May 2013 serum and urine immunofixation and FLC became negative. In September 2014, an increase of kappa FLC was observed, while serum and urine immunofixations remained negative until January 2015, when urine immunofixation became positive. Eventually, in February 2015, serum immunofixation revealed the presence of a free kappa MC. After a new BMB showing 80% of monotypic kappa PCs, a LCE relapse was diagnosed and the patient started the treatment with bendamustine, bortezomib and dexamethasone. In the present case, the increase of kappa FLC has indicated relapse 4 and 5 months earlier than urine and serum IFE, respectively. Our observation confirms that it is advisable to routinely perform FLC or BJP during follow up of MM patients undergoing ASCT and/or treatment with biological drugs to ensure that LCE is not missed.

scholarly journals Septal Nasal Extramedullary Plasmacytoma: A Rare Tumor in an Unusual Area

2020 ◽  
pp. 014556132091173
Author(s):  
Arianna Di Stadio ◽  
Massimo Ralli ◽  
Daniela Messineo ◽  
Giuseppe Ciancia ◽  
Annamaria Cascone ◽  
...  
Keyword(s):  
Nasal Septum ◽  
Rare Case ◽  
Extramedullary Plasmacytoma ◽  
Rare Tumor ◽  
Short Cycle ◽  
Systemic Involvement

We present an extreme rare case of extramedullary nasal plasmacitoma that arise from nasal septum. The mass surgically removed was analyzed by a pathologist who diagnosed an extramedullary nasal plasmacytoma. The patient did not present systemic involvement. A short cycle of radiotherapy was performed after the surgery. At 9-month follow-up, the patient is recurrence free.

scholarly journals The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing's syndrome

2008 ◽  
Vol 159 (5) ◽  
pp. 569-576 ◽  
Author(s):  
Giuseppe Reimondo ◽  
Silvia Bovio ◽  
Barbara Allasino ◽  
Silvia De Francia ◽  
Barbara Zaggia ◽  
...  
Keyword(s):  
Cushing’S Syndrome ◽  
Low Dose ◽  
Cushing's Syndrome ◽  
The Other ◽  
Screening Tests ◽  
Corticotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Dexamethasone Suppression ◽  
Rule Out

ObjectiveIt remains to be evaluated whether the combined low-dose dexamethasone suppression corticotropin-releasing hormone test (LDDST-CRH test) may add to the diagnostic approach of patients suspected to have Cushing's syndrome (CS). The aim of the present study was to evaluate whether the LDDST-CRH test may have a place in the diagnostic strategy of CS.DesignProspective evaluation of a consecutive series of patients with suspected CS from 2004 to 2006.MethodsAll the subjects underwent the same screening protocol including 1 mg dexamethasone suppression test, 24-h urinary free cortisol (UFC), and midnight serum cortisol, followed by the LDDST-CRH test whose results were not used to establish a definitive diagnosis. Plasma dexamethasone concentration was measured 2 h after the last dose of dexamethasone. Patients qualified for CS when at least two screening tests were positive.ResultsSixteen patients had CS while in the remaining 15 subjects CS was excluded. Even if not statistically significant, the sensitivity and the negative predictive value of the cortisol 15 min after CRH were better than the other tests; on the other hand, the test specificity was lower. All of the patients classified as indeterminate were correctly diagnosed by the LDDST-CRH test. Nevertheless, the repeated assessment of the screening tests and the active follow-up gave the same correct results. In all of the patients misclassified by the LDDST-CRH test, the plasma dexamethasone concentrations were in the normal range.ConclusionsBased on our findings, we suggest that the LDDST-CRH test may still find a place as a rule-out procedure in patients who present with indeterminate results after screening and may be unavailable to repeat testing during follow-up.

Sign in / Sign up

Export Citation Format

Share Document